Botulinum Toxin for Urinary Tract Disease
Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techn...
Salvato in:
| Natura: | Online |
|---|---|
| Lingua: | inglese |
| Pubblicazione: |
MDPI - Multidisciplinary Digital Publishing Institute
2026
|
| Soggetti: | |
| Accesso online: | ONIX_20260416T142754_9783725863389_7 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| Riassunto: | Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector? |
|---|